PMID: 8942463Dec 1, 1996Paper

D-cycloserine added to clozapine for patients with schizophrenia

The American Journal of Psychiatry
D C GoffJoseph T Coyle

Abstract

The effects of D-cycloserine added to clozapine were assessed and compared with previous results for D-cycloserine plus conventional neuroleptics. Ten schizophrenic outpatients receiving clozapine entered consecutive 2-week trials of placebo and D-cycloserine at 5, 15, 50, and 250 mg/day. Clinical evaluations were videotaped and scored by a rater blind to the sequence of assessments. There was a significant dose effect of D-cycloserine on scores on the Scale for the Assessment of Negative Symptoms (SANS); the 50-mg dose produced a mean 21% increase in SANS score. The patients had significantly higher baseline serum glutamate concentrations than the patients receiving typical neuroleptics in the previous trial. Baseline glutamate level and change in glycine level significantly correlated with response of negative symptoms to 50-mg D-cycloserine. The improvement of negative symptoms with D-cycloserine previously observed in patients receiving typical neuroleptics did not occur in patients treated with clozapine.

Citations

Jul 17, 2008·Current Psychiatry Reports·Michael A Webber, Stephen R Marder
Dec 4, 2003·Progress in Neuro-psychopharmacology & Biological Psychiatry·Uriel Heresco-Levy
Jan 23, 1999·Biological Psychiatry·J I FriedmanK L Davis
Dec 4, 1998·Biological Psychiatry·G TsaiJ T Coyle
Jan 7, 1998·Schizophrenia Research·D C Goff, L Wine
Oct 8, 2004·Schizophrenia Research·Sarah M Clinton, James H Meador-Woodruff
Feb 1, 2003·Pharmacology & Therapeutics·Christine Konradi, Stephan Heckers
Sep 13, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Stefano PorcelliAlessandro Serretti
Apr 6, 2011·Pharmacology, Biochemistry, and Behavior·Chieh-Hsin LinGuochuan E Tsai
Jan 26, 2010·Psychiatry Research·Jaromir HonsJan Libiger
Aug 22, 2009·Neuroscience and Biobehavioral Reviews·Viviane Labrie, John C Roder
May 25, 2016·The Psychiatric Clinics of North America·Ganesh GopalakrishnaJohn Lauriello
Feb 12, 2008·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Sabine A FuchsTom J de Koning
Aug 28, 2007·The Psychiatric Clinics of North America·Helio Elkis
Jun 6, 2013·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Donald C Goff
Oct 12, 2004·Schizophrenia Research·Erica J DuncanJohn P Rotrosen
Nov 7, 2008·Biological Psychiatry·Daphne J HoltDonald C Goff
Aug 26, 2006·Schizophrenia Research·Brendan P MurphyPatrick D McGorry
Sep 29, 2004·Biochemical Pharmacology·Joseph T Coyle
Sep 14, 2015·The International Journal of Neuropsychopharmacology·Sebastian Schade, Walter Paulus
Jun 8, 2011·Schizophrenia Research·Neal R Swerdlow
Sep 11, 2010·Progress in Neuro-psychopharmacology & Biological Psychiatry·Tohru Ohnuma, Heii Arai
Dec 2, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·John D SalamonePhilip McGuire
Aug 14, 2013·Schizophrenia Research·Celso ArangoStephen R Marder
Apr 17, 2012·Journal of Psychiatric Research·Jaromir HonsJan Libiger
Aug 6, 1999·Biological Psychiatry·W T CarpenterB Kirkpatrick
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Guochuan Tsai, Joseph T Coyle
Sep 19, 2012·Schizophrenia Bulletin·Joseph T Coyle
Oct 27, 2009·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·C ChavesJ E Hallak
Oct 31, 2002·Human Psychopharmacology·Brendan Belsham
Dec 6, 2001·Hippocampus·J W Newcomer, J H Krystal
Jan 15, 2015·Journal of Psychopharmacology·John Dunlop, Nicholas J Brandon

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here